PCI Biotech file patents for combination of siRNA and the PCI technology

21-Mar-2007

Photocure's daughter company PCI Biotech is developing a proprietary technology for site-specific drug delivery and drug enhancement called Photochemical Internalisation (PCI). PCI Biotech has, according to an agreement with Rikshospitalet-Radiumhospitalet HF, filed two patent applications covering the combination of siRNA (short interfering RNA) and the PCI technology. PCI Biotech plans to explore this field of the PCI-technology and will sponsor a dedicated research position within this field the next three years.

Kjetil Hestdal, President and CEO of Photocure, says: "Achieving safe and efficient gene delivery in the body has been a major limiting factor in the development of gene therapy. Our goal is to develop an effective treatment of cancer therapy through the combination of siRNA and the PCI technology."

Other news from the department research and development

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy